 This is an open label, non-randomized, dose escalation Phase I study evaluating the repeated intratumoral administrations of the TBI-1401HF10, a spontaneously attenuated mutant of HSV-1, in patients with solid tumors with superficial lesions e.g., malignant melanoma and squamous cell carcinoma of the skin. 